Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test could detect hidden pancreatic tumors

NCT ID NCT05847855

Diagnosis Sponsor: Fudan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new blood test that looks at fragments of DNA to find pancreatic neuroendocrine tumors early and tell them apart from other pancreatic tumors. Researchers will collect blood from 1,000 adults with different types of pancreatic tumors to see how accurate the test is. If it works, it could lead to earlier detection and better treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this blood test could help doctors find pancreatic neuroendocrine tumors earlier and avoid unnecessary surgeries by distinguishing tumor types.
What could go wrong
This is an early diagnostic study, not a treatment. The test may not be accurate enough in real-world settings, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2023

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population enrolled by the main center and the sub-center is uniformly divided into four groups with the same enrollment criteria for all. 1. pNET Group: Not receiving anti-tumor treatment before surgery, and were histopathologically confirmed pancreatic neuroendocrine tumors. 2. PDAC group: Patients with histopathologically confirmed pancreatic ductal adenocarcinoma (PDAC) who have not received any anti-tumor treatment before surgery. 3. SPT group: Patients with histopathologically confirmed solid pseudopapillary tumor (SPT) of the pancreas who have not received any anti-tumor treatment before surgery. 4. Healthy group: Healthy volunteers without a history of tumors and no pancreatic organic diseases.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 and above, regardless of gender; * Histopathological diagnosis with non-functional pancreatic neuroendocrine tumor, pancreatic ductal adenocarcinoma or solid pseudopapillary tumor; * Not receiving any anti-tumor treatment before surgery, including chemotherapy, embolization, ablation, radiotherapy, and molecular targeted therapy; * No obvious surgical contraindications; * Able to comply with research plans, follow-up plans, and other protocol requirements; * Voluntary participation and signed informed consent. Exclusion Criteria: * Pathological diagnosis was not pancreatic neuroendocrine tumor, pancreatic ductal adenocarcinoma or solid pseudopapillary tumor; * Currently diagnosed with other types of tumors or any cancer history; * Diagnosed with familial syndromes; * Receiving anti-tumor treatment before surgery, including chemotherapy, embolization, ablation, radiotherapy, and molecular targeted therapy; * Ongoing fever or recipient of anti-inflammation therapy within 14 days prior to study blood draw; * Recipient of blood transfusion within 30 days prior to study blood draw; * Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant; * Poor health condition and not suitable for blood draw; * Any other disease/condition deemed not suitable for study enrollment by researcher.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pancreatic ductal adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Adenoma, Islet Cell pancreatic ductal adenocarcinoma pancreatic neoplasm pancreatic neuroendocrine tumor solid pseudopapillary neoplasm of the pancreas

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreatic neuroendocrine tumor Solid pancreatic neoplasms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fudan University shanghai cancer center

    RECRUITING

    Shanghai, Shanghai Municipality, 200032, China

  • West China Hospital, Sichuan University

    RECRUITING

    Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.